Setidegrasib

Astellas\' new goal is to generate cumulative cost savings of 200 billion yen ($1.3 billion) from now until 2030.\n Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing to tighten its belt.The Japanese pharma may be expecting to rake in sales of 2.2 trillion yen ($13 billion) from Xtandi this year, but this is likely to be as good as it gets for the Pfizer-partnered blockbuster going forward. Astellas’ own slides show these prostate cancer sales withering away toward a “pipeline-led inflection point” in 2029.To prepare for this eventuality, the company unveiled a corporate multi-year strategic plan (PDF) Tuesday morning that will act as a roadmap for the pharma to hit “sustainable growth.”Part of this plan involves pursuing “value-enhancing [business development] with target and discipline.” Astellas is on the hunt for “synergistic assets” that will already be “moderately derisked.” The ultimate goal is to hit “record-high revenue” in the mid-2030s.While the company didn’t offer any clues as to which specific meds it may already have in its sights, Astellas did confirm in the strategy documents that these would typically be in “pre-defined therapeutic areas/modalities to add value through our established capabilities.”Beyond licensing individual drugs, Astellas didn’t rule out a “large-scale asset/company acquisition” as a way to protect its near-term revenue. In this case, a deal would likely “focus on near-launch or marketed assets,” the pharma explained.However, a high-value acquisition of this nature—which the company described as “rescue BD” —would not be “pursued by default.” Even with its existing clinical-stage pipeline, Astellas is hoping to reap 1 trillion yen ($6 billion) in combined potential revenue by the mid-2030s. The most advanced of these assets is the KRAS G12D-targeting protein degrader setidegrasib, which is in phase 3 studies for both first-line pancreatic ductal adenocarcinoma and second-line non‑small cell lung cancer.Beyond setidegrasib are the likes of ASP2138, an LDN18.2xCD3 bispecific T-cell engager being readied for a phase 3 study in gastroesophageal junction adenocarcinoma, and ASP7317, a cell therapy being developed for geographic atrophy secondary to age-related macular degeneration.This morning’s multi-year plan follows a multi-year cost-optimization program called “sustainable margin transformation,” which Astellas launched in 2024. Through organizational restructuring, streamlining certain infrastructure and reducing investments in mature products, Astellas already saved about 11 billion yen in selling, general and administrative expenses during fiscal 2025. Ongoing cost-reduction efforts mean that the company has previously said it expects SG&A expenses to decrease by 7% to 800 billion yen in fiscal 2026.But Astellas plans to go further still, alluding in this morning’s documents to “additional initiatives” required to reduce costs over the next four years. The new goal is to generate cumulative cost savings of 200 billion yen ($1.3 billion) from now until 2030.Astellas didn\'t directly answer Fierce’s question about whether these initiatives are likely to involve laying off employees. Instead, a spokesperson pointed out that the strategy would involve a “robust prioritization to place additional emphasis on geographies, disease areas, and modalities in which Astellas has the strongest capabilities and growth potential.”These plans also require “mindset shifts to focus on driving impact,” the spokesperson added.While the company clearly decided more work was needed to prepare for the group-wide revenue decline once Xtandi falls off the patent cliff, the financial picture for fiscal year 2026 has been looking rosy. In its most recent earnings results, Astellas said it expects five strategic brands will deliver 130 billion yen in additional sales this year—which would represent 27% growth—and will therefore drive overall company growth by 4% year over year.The five products are Pfizer-partnered antibody-drug conjugate Padcev, eye med Izervay, CLDN18.2 cancer drug Vyloy, menopause therapy Veozah and leukemia treatment Xospata. This group of drugs, which Astellas refers to as its “strategic brands,” plays a key role in the company’s latest strategy. The plan is for these meds to account for over 50% of Astellas’ revenue in 2030, compared to around 23% in 2025.Doubling the sales of these therapies in the next few years will require a successful readout of an ongoing phase 3 trial for Padcev in an additional type of bladder cancer, as well as launching a pre-filled syringe version of Izervay and marketing Vyloy in China, among other opportunities.“Astellas is well-positioned to deliver strong performance and greater value faster for patients through 2030 and beyond,” Astellas CEO Naoki Okamura said in a statement.“With Strategic Brands driving momentum and a pipeline built on new targets, advanced modalities and precision approaches, we are primed to achieve record-high revenue in the mid-2030s—driven by pipeline-led growth—while addressing areas of high unmet medical need,” Okamura added.

Astellas eyes pipeline deals as Xtandi revenues near peakEditas plans to raise up to $319.4M Cartesian inks $150M credit deal to stay operational into 2028 Astellas eyes pipeline deals as Xtandi revenues near peakAstellas unveiled a five-year growth strategy Tuesday as it looks to cushion the blow from the eventual patent expiry of its prostate cancer drug Xtandi (enzalutamide). The Japanese drugmaker expects sales to peak at about JPY 2.2 trillion ($13.8 billion) in fiscal 2026, before beginning a decline — impacted by Xtandi's upcoming loss of exclusivity, as well as US price reductions on the drug tied to the Inflation Reduction Act — that will reach a "pipeline-led inflection point" by fiscal 2029.The company will be looking to counteract that by bolstering its pipeline through the acquisition of "moderately derisked assets and pre-defined therapeutic areas/modalities." It is also leaving the door open to larger acquisitions as a "rescue" business development strategy that would bring in near-launch or marketed products, though these purchases will "not [be] pursued by default."Astellas said it is targeting JPY 1 trillion ($6.3 billion) in pipeline-driven revenue by the mid-2030s, highlighting the Phase III asset setidegrasib (ASP3082), a KRAS G12D degrader being tested in lung and pancreatic cancers; the T-cell engager ASP2138 and antibody-drug conjugate ASP546C, CLDN18.2-targeting therapies being developed for gastric/gastroesophageal junction cancers; and retinal cell therapy ASP7317. The pharma also indicated it has a "recurring cost optimisation target" of JPY 200 billion ($1.3 billion) by 2030.-Anna BratulicEditas plans to raise up to $319.4M Editas Medicine raised $125 million on Tuesday through the sale of 55.6 million shares and accompanying warrants at $2.25.The warrants are exercisable immediately at $3.50 per share, though they will expire in three years, or 30 days after Editas presents Phase I data on EDIT-401 from three patients demonstrating greater than 80% reduction in LDL cholesterol (LDL-C) from baseline with at least one month of follow-up, whichever comes first. If all warrants are exercised, Editas will net an additional $194.4 million. Meanwhile, the drugmaker shared preclinical data for EDIT-401, an in vivo gene editing candidate designed to directly edit the LDLR gene and reduce LDL-C. In non-human primates, a single dose of EDIT-401 led to roughly 90% or greater mean reductions in LDL-C, Lp(a), and ApoB. -Elizabeth EatonCartesian inks $150M credit deal to stay operational into 2028Cartesian Therapeutics said Tuesday that it has signed a deal with investment firm K2 HealthVentures for a credit facility of up to $150 million. The autoimmune disease-focused company will be able to draw from an initial $50-million tranche to prepare for the potential commercial launch of Descartes-08 in myasthenia gravis (MG) and myositis.Descartes-08 is an autologous BCMA-targeted mRNA CAR-T cell therapy. In April, Cartesian reported Phase IIb data showing that patients with generalised MG taking the experimental CAR-T showed sustained benefits through 12 months. The drugmaker expects top-line data from the Phase III AURORA MG trial in the first quarter of 2027, and it plans to file a BLA in the middle of that year. The first tranche from the credit facility will lengthen Cartesian's cash runway into 2028. The second $25 million loan can be drawn between Jan. 1, 2027 and Dec. 1, 2027, and the third $25 million portion should be available between Jan. 1, 2028 and June 1, 2028, both subject to certain clinical and financing milestones. The final $50 million tranche is only available at K2 HealthVentures’ discretion. -Elizabeth Eaton